⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for bromodomain

Every month we try and update this database with for bromodomain cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast CancerNCT03901469
Triple Negative...
ZEN003694
Talazoparib
18 Years - Zenith Epigenetics
A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate CancerNCT02705469
Metastatic Cast...
ZEN003694
18 Years - Zenith Epigenetics
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric CancerNCT03936465
Solid Tumor, Ch...
Lymphoma
Brain Tumor, Pe...
BMS-986158
BMS-986378
1 Year - 21 YearsDana-Farber Cancer Institute
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate CancerNCT04986423
Metastatic Cast...
ZEN003694
Enzalutamide
18 Years - Zenith Epigenetics
A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast CancerNCT03901469
Triple Negative...
ZEN003694
Talazoparib
18 Years - Zenith Epigenetics
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate CancerNCT04986423
Metastatic Cast...
ZEN003694
Enzalutamide
18 Years - Zenith Epigenetics
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: